MeSH term
Frequency | Condition_Probility | Animals | 42 | 0.0 |
Cell Line | 18 | 0.0 |
*Chromosome Aberrations | 2 | 0.0 |
Humans | 69 | 0.0 |
Research Support, Non-U.S. Gov't | 54 | 0.0 |
Tumor Cells, Cultured | 8 | 0.0 |
Cell Division/*drug effects | 2 | 0.0 |
Enzyme Activation | 3 | 0.0 |
Glucose/*pharmacology | 2 | 2.0 |
Insulin/*pharmacology | 4 | 1.0 |
Kinetics | 5 | 0.0 |
Mice | 15 | 0.0 |
Phosphoproteins/metabolism | 6 | 0.0 |
Receptor, Insulin/metabolism | 3 | 3.0 |
1-Phosphatidylinositol 3-Kinase/metabolism | 6 | 1.0 |
Cells, Cultured | 10 | 0.0 |
Comparative Study | 11 | 0.0 |
*Down-Regulation | 2 | 0.0 |
Immunoblotting | 2 | 0.0 |
Insulin Resistance/*physiology | 3 | 4.0 |
Phosphoproteins/*metabolism | 8 | 1.0 |
Proteins/metabolism | 2 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 27 | 0.0 |
*Signal Transduction | 4 | 0.0 |
DNA Damage | 2 | 0.0 |
DNA Repair/*genetics | 5 | 1.0 |
DNA-Binding Proteins/*genetics | 2 | 0.0 |
Dose-Response Relationship, Radiation | 4 | 1.0 |
Genetic Complementation Test | 9 | 1.0 |
Hamsters | 18 | 0.0 |
Mutation | 3 | 0.0 |
Radiation Tolerance/genetics | 3 | 6.0 |
Transfection | 10 | 0.0 |
*Adaptor Proteins, Signal Transducing | 8 | 0.0 |
*Adaptor Proteins, Vesicular Transport | 2 | 0.0 |
CHO Cells | 4 | 0.0 |
Phosphorylation | 13 | 0.0 |
Receptor, Insulin/*metabolism | 3 | 5.0 |
Signal Transduction | 10 | 0.0 |
Homeostasis | 3 | 0.0 |
Insulin/*physiology | 2 | 4.0 |
Mice, Knockout | 3 | 0.0 |
Receptor, Insulin/*physiology | 2 | 22.0 |
Enzyme Activation/drug effects | 3 | 0.0 |
Leptin/*pharmacology | 3 | 10.0 |
Phosphoproteins/*physiology | 2 | 2.0 |
Rats | 9 | 0.0 |
src Homology Domains | 2 | 0.0 |
Male | 13 | 0.0 |
Mitogen-Activated Protein Kinases/metabolism | 5 | 0.0 |
Muscle, Skeletal/metabolism | 2 | 1.0 |
Protein-Serine-Threonine Kinases/metabolism | 5 | 0.0 |
Proto-Oncogene Proteins/metabolism | 8 | 0.0 |
Signal Transduction/physiology | 2 | 0.0 |
Cricetulus | 7 | 1.0 |
Drug Resistance | 2 | 0.0 |
Phenotype | 4 | 0.0 |
Base Sequence | 11 | 0.0 |
DNA Mutational Analysis | 2 | 0.0 |
Polymorphism, Genetic | 2 | 0.0 |
Adult | 11 | 0.0 |
Aged | 7 | 0.0 |
Aged, 80 and over | 2 | 0.0 |
Case-Control Studies | 5 | 0.0 |
Female | 12 | 0.0 |
Genotype | 5 | 0.0 |
Insulin-Like Growth Factor I/*genetics | 2 | 8.0 |
Middle Aged | 9 | 0.0 |
Polymorphism, Genetic/*genetics | 3 | 0.0 |
Amino Acid Sequence | 4 | 0.0 |
Chromosome Aberrations | 2 | 0.0 |
*DNA Damage | 2 | 0.0 |
Molecular Sequence Data | 13 | 0.0 |
Mutagenesis, Site-Directed | 2 | 0.0 |
Sequence Homology, Amino Acid | 3 | 0.0 |
Alleles | 2 | 0.0 |
Phosphoproteins/*genetics | 7 | 2.0 |
Polymerase Chain Reaction | 2 | 0.0 |
Questionnaires | 2 | 0.0 |
Risk Factors | 2 | 0.0 |
Utah/epidemiology | 2 | 25.0 |
Diabetes Mellitus, Type 2/genetics | 2 | 4.0 |
Insulin Resistance/*genetics | 2 | 2.0 |
Receptor, Insulin/*genetics | 3 | 7.0 |
*Insulin Resistance | 2 | 1.0 |
Hybrid Cells | 5 | 0.0 |
In Situ Hybridization, Fluorescence | 2 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 5 | 0.0 |
Species Specificity | 2 | 0.0 |
Genetic Markers | 4 | 0.0 |
Biological Transport | 3 | 0.0 |
Glucose/*metabolism | 2 | 1.0 |
Insulin/pharmacology | 3 | 1.0 |
*Protein-Serine-Threonine Kinases | 5 | 0.0 |
Insulin/*metabolism | 2 | 2.0 |
Signal Transduction/*physiology | 3 | 0.0 |
Phosphoproteins/genetics/metabolism | 2 | 2.0 |
Protein Structure, Tertiary | 3 | 0.0 |
Hela Cells | 2 | 0.0 |
Precipitin Tests | 2 | 0.0 |
Chromosome Mapping | 4 | 0.0 |
Cosmids | 2 | 0.0 |
Restriction Mapping | 4 | 0.0 |
Cytomegalovirus/*genetics | 5 | 13.0 |
*Genes, Viral | 4 | 2.0 |
*Trans-Activation (Genetics) | 2 | 0.0 |
Cycloheximide/pharmacology | 2 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 2 | 0.0 |
Time Factors | 4 | 0.0 |
Cell Survival | 2 | 0.0 |
Dose-Response Relationship, Drug | 3 | 0.0 |
*DNA Replication | 2 | 0.0 |
*Gene Expression Regulation, Viral | 3 | 1.0 |
Genes, Immediate-Early | 2 | 3.0 |
Immediate-Early Proteins/genetics | 2 | 4.0 |
Gamma Rays | 2 | 0.0 |
Diabetes Mellitus, Type 2/*genetics | 2 | 1.0 |
Obesity | 2 | 3.0 |
Cytomegalovirus/*genetics/growth & development | 2 | 100.0 |
Oligonucleotides | 2 | 3.0 |
Child | 2 | 0.0 |
Protein-Tyrosine Kinase/metabolism | 2 | 0.0 |
Proteins/*metabolism | 2 | 0.0 |
Gene Expression | 2 | 0.0 |
Son of Sevenless Proteins | 2 | 3.0 |
Plasmids | 2 | 0.0 |
Radiation Tolerance/*genetics | 2 | 3.0 |
Proteins/*physiology | 2 | 1.0 |
Viral Proteins/metabolism | 2 | 2.0 |
DNA/genetics | 2 | 0.0 |
Cloning, Molecular | 3 | 0.0 |
Tyrosine/metabolism | 2 | 0.0 |
Oligodeoxyribonucleotides | 2 | 0.0 |
Polymerase Chain Reaction/methods | 2 | 0.0 |
Adipocytes/metabolism | 2 | 4.0 |
Insulin Resistance | 3 | 1.0 |
Adolescent | 3 | 0.0 |
Viral Proteins/*genetics/metabolism | 2 | 11.0 |
*Mutation | 4 | 0.0 |
Proto-Oncogene Proteins/genetics/*metabolism | 2 | 0.0 |
Phosphoproteins/genetics/*metabolism | 2 | 1.0 |
DNA Repair | 2 | 0.0 |
Ataxia Telangiectasia/*genetics | 2 | 3.0 |
Serine/*metabolism | 2 | 2.0 |
*Intracellular Signaling Peptides and Proteins | 2 | 0.0 |
Choriocarcinoma | 2 | 5.0 |
Uterine Neoplasms | 2 | 15.0 |
Mice, Inbred C57BL | 2 | 0.0 |
Glucose/metabolism | 2 | 0.0 |
